New vaccine adoption in lower-middle-income countries

Objectives Lower-middle-income countries (LMICs) are lagging behind both high-income and low-income countries in new vaccine adoption. Our study involved the following objectives: (1) understand the decision-making processes of LMICs on new vaccine adoption, (2) identify the factors influencing LMIC...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Health policy and planning 2012-05, Vol.27 (suppl_2), p.ii39-ii49
Hauptverfasser: Makinen, Marty, Kaddar, Miloud, Molldrem, Vivikka, Wilson, Lara
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page ii49
container_issue suppl_2
container_start_page ii39
container_title Health policy and planning
container_volume 27
creator Makinen, Marty
Kaddar, Miloud
Molldrem, Vivikka
Wilson, Lara
description Objectives Lower-middle-income countries (LMICs) are lagging behind both high-income and low-income countries in new vaccine adoption. Our study involved the following objectives: (1) understand the decision-making processes of LMICs on new vaccine adoption, (2) identify the factors influencing LMIC decisions, (3) obtain the views of vaccine manufacturers about LMIC markets for new vaccines, and (4) make recommendations concerning how to speed up and improve decision making, including proposing mechanisms for implementation of the recommendations. Methods Collect and analyse qualitative data from participants in decision making in 15 case study countries [12 LMICs and three upper-middle-income countries (UMICs)] and multinational and developing country vaccine manufacturers. Findings Interviews of actors in decision making indicate that the aspects deemed most important for adoption are: World Health Organization (WHO) recommendations, the existence of local epidemiological data and a set of factors comprising affordability, cost-effectiveness and overall cost of the new vaccine for the programme. National Immunization Technical Advisory Groups (NITAG) have a key role in advising decision-makers, although their resources and capacity vary. Country decision-makers and manufacturers both see advantages in pooled procurement mechanisms for vaccine purchasing. Recommendations for countries and the international community involve assisting with making epidemiological data and vaccine market information accessible to countries, building and reinforcing related analysis capacity, and assisting with purchasing mechanisms and practices such as pooled procurement.
doi_str_mv 10.1093/heapol/czs036
format Article
fullrecord <record><control><sourceid>jstor_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_1257731524</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><jstor_id>45090816</jstor_id><sourcerecordid>45090816</sourcerecordid><originalsourceid>FETCH-LOGICAL-c547t-b7cbc8b310da49ea907d27c3d1b53bd3de3a289c87be192fb6b57078d9f9a3ec3</originalsourceid><addsrcrecordid>eNqN0btP3EAQBvBVlChcLikpQZZo0jjMvjzeMkLkIaGkSWprH3PCJ9t77Nog8tdnkQlFGqim2J8-7czH2DGHTxyMPL8me4jDuf-TQTav2IarBmohJL5mGxBNW3No4Yi9y3kPwJVS-i07EkJziZJvmP5Bd9Wt9b6fqLIhHuY-TlU_VUO8o1SPfQgD1f3k40iVj8s0p57ye_ZmZ4dMHx7nlv3-cvnr4lt99fPr94vPV7XXCufaoXe-dZJDsMqQNYBBoJeBOy1dkIGkFa3xLTriRuxc4zQCtsHsjJXk5ZZ9XHMPKd4slOdu7LOnYbATxSV3XGgsa2ihXkBBo1CI8DzlmoNSAvB5Ci1vTaNQvoCC0SWzeaBn_9F9XNJULlm-iWiQy1LtltWr8inmnGjXHVI_2nRforqH7ru1-27tvvjTx9TFjRSe9L-yCzhZwT7PMT29Kw2mrNHIvyS6srI</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1277971309</pqid></control><display><type>article</type><title>New vaccine adoption in lower-middle-income countries</title><source>Applied Social Sciences Index &amp; Abstracts (ASSIA)</source><source>PubMed (Medline)</source><source>MEDLINE</source><source>PAIS Index</source><source>Alma/SFX Local Collection</source><source>JSTOR</source><source>EZB Electronic Journals Library</source><source>Oxford Open Access Journals</source><creator>Makinen, Marty ; Kaddar, Miloud ; Molldrem, Vivikka ; Wilson, Lara</creator><creatorcontrib>Makinen, Marty ; Kaddar, Miloud ; Molldrem, Vivikka ; Wilson, Lara</creatorcontrib><description>Objectives Lower-middle-income countries (LMICs) are lagging behind both high-income and low-income countries in new vaccine adoption. Our study involved the following objectives: (1) understand the decision-making processes of LMICs on new vaccine adoption, (2) identify the factors influencing LMIC decisions, (3) obtain the views of vaccine manufacturers about LMIC markets for new vaccines, and (4) make recommendations concerning how to speed up and improve decision making, including proposing mechanisms for implementation of the recommendations. Methods Collect and analyse qualitative data from participants in decision making in 15 case study countries [12 LMICs and three upper-middle-income countries (UMICs)] and multinational and developing country vaccine manufacturers. Findings Interviews of actors in decision making indicate that the aspects deemed most important for adoption are: World Health Organization (WHO) recommendations, the existence of local epidemiological data and a set of factors comprising affordability, cost-effectiveness and overall cost of the new vaccine for the programme. National Immunization Technical Advisory Groups (NITAG) have a key role in advising decision-makers, although their resources and capacity vary. Country decision-makers and manufacturers both see advantages in pooled procurement mechanisms for vaccine purchasing. Recommendations for countries and the international community involve assisting with making epidemiological data and vaccine market information accessible to countries, building and reinforcing related analysis capacity, and assisting with purchasing mechanisms and practices such as pooled procurement.</description><identifier>ISSN: 0268-1080</identifier><identifier>EISSN: 1460-2237</identifier><identifier>DOI: 10.1093/heapol/czs036</identifier><identifier>PMID: 22513731</identifier><identifier>CODEN: HPOPEV</identifier><language>eng</language><publisher>England: Oxford University Press</publisher><subject>Advisory Committees ; Advisory groups ; Case studies ; Comparative analysis ; Cost effectiveness ; Decision makers ; Decision making ; Decision Making, Organizational ; Developing Countries ; Epidemiology ; Health administration ; Health care policy ; Health initiatives ; Humans ; Immunization ; Immunization Programs - economics ; Immunization Programs - organization &amp; administration ; Low income ; Markets ; Middle income ; Original articles ; Policy Making ; Purchasing ; Studies ; Vaccination and vaccines ; Vaccines ; Vaccines - economics ; Vaccines - therapeutic use ; World Health Organization</subject><ispartof>Health policy and planning, 2012-05, Vol.27 (suppl_2), p.ii39-ii49</ispartof><rights>2012 Oxford University Press</rights><rights>Copyright Oxford Publishing Limited(England) May 2012</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c547t-b7cbc8b310da49ea907d27c3d1b53bd3de3a289c87be192fb6b57078d9f9a3ec3</citedby><cites>FETCH-LOGICAL-c547t-b7cbc8b310da49ea907d27c3d1b53bd3de3a289c87be192fb6b57078d9f9a3ec3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.jstor.org/stable/pdf/45090816$$EPDF$$P50$$Gjstor$$H</linktopdf><linktohtml>$$Uhttps://www.jstor.org/stable/45090816$$EHTML$$P50$$Gjstor$$H</linktohtml><link.rule.ids>314,780,784,803,27865,27866,27924,27925,30999,31000,58017,58250</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22513731$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Makinen, Marty</creatorcontrib><creatorcontrib>Kaddar, Miloud</creatorcontrib><creatorcontrib>Molldrem, Vivikka</creatorcontrib><creatorcontrib>Wilson, Lara</creatorcontrib><title>New vaccine adoption in lower-middle-income countries</title><title>Health policy and planning</title><addtitle>Health Policy Plan</addtitle><description>Objectives Lower-middle-income countries (LMICs) are lagging behind both high-income and low-income countries in new vaccine adoption. Our study involved the following objectives: (1) understand the decision-making processes of LMICs on new vaccine adoption, (2) identify the factors influencing LMIC decisions, (3) obtain the views of vaccine manufacturers about LMIC markets for new vaccines, and (4) make recommendations concerning how to speed up and improve decision making, including proposing mechanisms for implementation of the recommendations. Methods Collect and analyse qualitative data from participants in decision making in 15 case study countries [12 LMICs and three upper-middle-income countries (UMICs)] and multinational and developing country vaccine manufacturers. Findings Interviews of actors in decision making indicate that the aspects deemed most important for adoption are: World Health Organization (WHO) recommendations, the existence of local epidemiological data and a set of factors comprising affordability, cost-effectiveness and overall cost of the new vaccine for the programme. National Immunization Technical Advisory Groups (NITAG) have a key role in advising decision-makers, although their resources and capacity vary. Country decision-makers and manufacturers both see advantages in pooled procurement mechanisms for vaccine purchasing. Recommendations for countries and the international community involve assisting with making epidemiological data and vaccine market information accessible to countries, building and reinforcing related analysis capacity, and assisting with purchasing mechanisms and practices such as pooled procurement.</description><subject>Advisory Committees</subject><subject>Advisory groups</subject><subject>Case studies</subject><subject>Comparative analysis</subject><subject>Cost effectiveness</subject><subject>Decision makers</subject><subject>Decision making</subject><subject>Decision Making, Organizational</subject><subject>Developing Countries</subject><subject>Epidemiology</subject><subject>Health administration</subject><subject>Health care policy</subject><subject>Health initiatives</subject><subject>Humans</subject><subject>Immunization</subject><subject>Immunization Programs - economics</subject><subject>Immunization Programs - organization &amp; administration</subject><subject>Low income</subject><subject>Markets</subject><subject>Middle income</subject><subject>Original articles</subject><subject>Policy Making</subject><subject>Purchasing</subject><subject>Studies</subject><subject>Vaccination and vaccines</subject><subject>Vaccines</subject><subject>Vaccines - economics</subject><subject>Vaccines - therapeutic use</subject><subject>World Health Organization</subject><issn>0268-1080</issn><issn>1460-2237</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>7QJ</sourceid><sourceid>7TQ</sourceid><recordid>eNqN0btP3EAQBvBVlChcLikpQZZo0jjMvjzeMkLkIaGkSWprH3PCJ9t77Nog8tdnkQlFGqim2J8-7czH2DGHTxyMPL8me4jDuf-TQTav2IarBmohJL5mGxBNW3No4Yi9y3kPwJVS-i07EkJziZJvmP5Bd9Wt9b6fqLIhHuY-TlU_VUO8o1SPfQgD1f3k40iVj8s0p57ye_ZmZ4dMHx7nlv3-cvnr4lt99fPr94vPV7XXCufaoXe-dZJDsMqQNYBBoJeBOy1dkIGkFa3xLTriRuxc4zQCtsHsjJXk5ZZ9XHMPKd4slOdu7LOnYbATxSV3XGgsa2ihXkBBo1CI8DzlmoNSAvB5Ci1vTaNQvoCC0SWzeaBn_9F9XNJULlm-iWiQy1LtltWr8inmnGjXHVI_2nRforqH7ru1-27tvvjTx9TFjRSe9L-yCzhZwT7PMT29Kw2mrNHIvyS6srI</recordid><startdate>20120501</startdate><enddate>20120501</enddate><creator>Makinen, Marty</creator><creator>Kaddar, Miloud</creator><creator>Molldrem, Vivikka</creator><creator>Wilson, Lara</creator><general>Oxford University Press</general><general>Oxford Publishing Limited (England)</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QJ</scope><scope>7T2</scope><scope>7TQ</scope><scope>8BJ</scope><scope>C1K</scope><scope>DHY</scope><scope>DON</scope><scope>FQK</scope><scope>JBE</scope><scope>K9.</scope><scope>7X8</scope><scope>7U2</scope></search><sort><creationdate>20120501</creationdate><title>New vaccine adoption in lower-middle-income countries</title><author>Makinen, Marty ; Kaddar, Miloud ; Molldrem, Vivikka ; Wilson, Lara</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c547t-b7cbc8b310da49ea907d27c3d1b53bd3de3a289c87be192fb6b57078d9f9a3ec3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Advisory Committees</topic><topic>Advisory groups</topic><topic>Case studies</topic><topic>Comparative analysis</topic><topic>Cost effectiveness</topic><topic>Decision makers</topic><topic>Decision making</topic><topic>Decision Making, Organizational</topic><topic>Developing Countries</topic><topic>Epidemiology</topic><topic>Health administration</topic><topic>Health care policy</topic><topic>Health initiatives</topic><topic>Humans</topic><topic>Immunization</topic><topic>Immunization Programs - economics</topic><topic>Immunization Programs - organization &amp; administration</topic><topic>Low income</topic><topic>Markets</topic><topic>Middle income</topic><topic>Original articles</topic><topic>Policy Making</topic><topic>Purchasing</topic><topic>Studies</topic><topic>Vaccination and vaccines</topic><topic>Vaccines</topic><topic>Vaccines - economics</topic><topic>Vaccines - therapeutic use</topic><topic>World Health Organization</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Makinen, Marty</creatorcontrib><creatorcontrib>Kaddar, Miloud</creatorcontrib><creatorcontrib>Molldrem, Vivikka</creatorcontrib><creatorcontrib>Wilson, Lara</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Applied Social Sciences Index &amp; Abstracts (ASSIA)</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>PAIS Index</collection><collection>International Bibliography of the Social Sciences (IBSS)</collection><collection>Environmental Sciences and Pollution Management</collection><collection>PAIS International</collection><collection>PAIS International (Ovid)</collection><collection>International Bibliography of the Social Sciences</collection><collection>International Bibliography of the Social Sciences</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><collection>Safety Science and Risk</collection><jtitle>Health policy and planning</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Makinen, Marty</au><au>Kaddar, Miloud</au><au>Molldrem, Vivikka</au><au>Wilson, Lara</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>New vaccine adoption in lower-middle-income countries</atitle><jtitle>Health policy and planning</jtitle><addtitle>Health Policy Plan</addtitle><date>2012-05-01</date><risdate>2012</risdate><volume>27</volume><issue>suppl_2</issue><spage>ii39</spage><epage>ii49</epage><pages>ii39-ii49</pages><issn>0268-1080</issn><eissn>1460-2237</eissn><coden>HPOPEV</coden><abstract>Objectives Lower-middle-income countries (LMICs) are lagging behind both high-income and low-income countries in new vaccine adoption. Our study involved the following objectives: (1) understand the decision-making processes of LMICs on new vaccine adoption, (2) identify the factors influencing LMIC decisions, (3) obtain the views of vaccine manufacturers about LMIC markets for new vaccines, and (4) make recommendations concerning how to speed up and improve decision making, including proposing mechanisms for implementation of the recommendations. Methods Collect and analyse qualitative data from participants in decision making in 15 case study countries [12 LMICs and three upper-middle-income countries (UMICs)] and multinational and developing country vaccine manufacturers. Findings Interviews of actors in decision making indicate that the aspects deemed most important for adoption are: World Health Organization (WHO) recommendations, the existence of local epidemiological data and a set of factors comprising affordability, cost-effectiveness and overall cost of the new vaccine for the programme. National Immunization Technical Advisory Groups (NITAG) have a key role in advising decision-makers, although their resources and capacity vary. Country decision-makers and manufacturers both see advantages in pooled procurement mechanisms for vaccine purchasing. Recommendations for countries and the international community involve assisting with making epidemiological data and vaccine market information accessible to countries, building and reinforcing related analysis capacity, and assisting with purchasing mechanisms and practices such as pooled procurement.</abstract><cop>England</cop><pub>Oxford University Press</pub><pmid>22513731</pmid><doi>10.1093/heapol/czs036</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0268-1080
ispartof Health policy and planning, 2012-05, Vol.27 (suppl_2), p.ii39-ii49
issn 0268-1080
1460-2237
language eng
recordid cdi_proquest_miscellaneous_1257731524
source Applied Social Sciences Index & Abstracts (ASSIA); PubMed (Medline); MEDLINE; PAIS Index; Alma/SFX Local Collection; JSTOR; EZB Electronic Journals Library; Oxford Open Access Journals
subjects Advisory Committees
Advisory groups
Case studies
Comparative analysis
Cost effectiveness
Decision makers
Decision making
Decision Making, Organizational
Developing Countries
Epidemiology
Health administration
Health care policy
Health initiatives
Humans
Immunization
Immunization Programs - economics
Immunization Programs - organization & administration
Low income
Markets
Middle income
Original articles
Policy Making
Purchasing
Studies
Vaccination and vaccines
Vaccines
Vaccines - economics
Vaccines - therapeutic use
World Health Organization
title New vaccine adoption in lower-middle-income countries
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T10%3A25%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-jstor_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=New%20vaccine%20adoption%20in%20lower-middle-income%20countries&rft.jtitle=Health%20policy%20and%20planning&rft.au=Makinen,%20Marty&rft.date=2012-05-01&rft.volume=27&rft.issue=suppl_2&rft.spage=ii39&rft.epage=ii49&rft.pages=ii39-ii49&rft.issn=0268-1080&rft.eissn=1460-2237&rft.coden=HPOPEV&rft_id=info:doi/10.1093/heapol/czs036&rft_dat=%3Cjstor_proqu%3E45090816%3C/jstor_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1277971309&rft_id=info:pmid/22513731&rft_jstor_id=45090816&rfr_iscdi=true